Search

Displaying results 5211 - 5220 of 10000 in total
  1. Drug

    Floctafenine

    go.drugbank.com/drugs/DB08976
    ApprovedWithdrawn

    Floctafenine is an anti-inflammatory analgesic similar in action to aspirin. Floctafenine inhibits prostaglandin synthesis.

  2. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

  3. Drug

    TD-0903

    go.drugbank.com/drugs/DB16463
    Investigational

    TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants … with supplemental oxygenation), and NCT04402866 (focused on ALI and lung inflammation associated with COVID-19)

  4. Drug

    Alimemazine

    go.drugbank.com/drugs/DB01246
    ApprovedVet approvedWithdrawn

    A phenothiazine derivative that is used as an antipruritic.

  5. Drug

    AT-301

    go.drugbank.com/drugs/DB16507
    Investigational

    AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine

  6. Drug

    Metergoline

    go.drugbank.com/drugs/DB13520
    Approved

    ] premenstrual dysphoric disorder in women and antianxiety treatment. … [A27181] Its use has been studied in various clinical settings such as a treatment for seasonal affective disorder, prolactin hormone regulation due to its inhibitory effect on prolactin release,[A27182

  7. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    It was under investigation in clinical trials to treat Inflammatory Arthritis. In 2007, one patient participating in the clinical trial died and the trial was placed on clinical hold by the FDA. … The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038]

  8. Drug

    Nilvadipine

    go.drugbank.com/drugs/DB06712
    Approved

    Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.

  9. Drug

    Gemopatrilat

    go.drugbank.com/drugs/DB20954
    Experimental

    Gemopatrilat is a small molecule drug. Gemopatrilat has a monoisotopic molecular weight of 378.16 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. … HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep.